{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=4", "query": { "condition": "Advanced Solid Neoplasm", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 3385, "total_pages": 339, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T03:42:56.536Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07807956", "title": "A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Non-Small Cell Lung Cancer", "Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Biliary Tract Cancer", "Head and Neck Squamous Cell Carcinoma", "Ovarian Cancer" ], "interventions": [ { "name": "ABBV-253", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2026-09-14", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-11-07T03:42:56.536Z", "location_count": 3, "location_summary": "Grand Rapids, Michigan • Huntersville, North Carolina • Irving, Texas", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07807956" }, { "nct_id": "NCT01602627", "title": "Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "Hsp90 inhibitor AUY922", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Dale Shepard, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "75 Years", "maximum_age": null, "sex": "ALL", "summary": "75 Years and older" }, "enrollment_count": 2, "start_date": "2011-09", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2013-02-07", "last_synced_at": "2026-11-07T03:42:56.536Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01602627" }, { "nct_id": "NCT04504942", "title": "Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "Leronlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CytoDyn, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2020-05-01", "completion_date": "2025-01-27", "has_results": true, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-11-07T03:42:56.536Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04504942" }, { "nct_id": "NCT04145622", "title": "Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Malignant Solid Tumor" ], "interventions": [ { "name": "Ifinatamab deruxtecan (I-DXd)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 247, "start_date": "2019-11-03", "completion_date": "2029-10-31", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-07T03:42:56.536Z", "location_count": 10, "location_summary": "Denver, Colorado • Sarasota, Florida • Boston, Massachusetts + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04145622" }, { "nct_id": "NCT04374877", "title": "Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "CHS-388", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Coherus Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2020-04-22", "completion_date": "2025-06-05", "has_results": false, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-11-07T03:42:56.536Z", "location_count": 18, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04374877" }, { "nct_id": "NCT00514267", "title": "An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Tumors" ], "interventions": [ { "name": "YM 155", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2007-05", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2015-08-13", "last_synced_at": "2026-11-07T03:42:56.536Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00514267" }, { "nct_id": "NCT01664000", "title": "A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "thioureidobutyronitrile", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellceutix Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2012-10", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2016-02-24", "last_synced_at": "2026-11-07T03:42:56.536Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01664000" }, { "nct_id": "NCT00700336", "title": "Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Pleural Mesothelioma", "Solid Tumors" ], "interventions": [ { "name": "pemetrexed, cisplatin and CBP501", "type": "DRUG" }, { "name": "pemetrexed and cisplatin", "type": "DRUG" }, { "name": "pemetrexed, cisplatin and CBP501, dose finding", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CanBas Co. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2008-05", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2021-07-20", "last_synced_at": "2026-11-07T03:42:56.536Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00700336" }, { "nct_id": "NCT04047862", "title": "Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced and Metastatic Solid Tumors" ], "interventions": [ { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "5fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 446, "start_date": "2019-08-15", "completion_date": "2024-08-07", "has_results": true, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-11-07T03:42:56.536Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Fort Myers, Florida • Jacksonville, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04047862" }, { "nct_id": "NCT05856981", "title": "Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Metastatic Solid Tumor", "Refractory Cancer", "CRC, Colorectal Cancer", "RCC, Clear Cell Adenocarcinoma", "NSCLC (Advanced Non-small Cell Lung Cancer)", "Endometrial Cancer" ], "interventions": [ { "name": "ADU-1805", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sairopa B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2023-04-03", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-07T03:42:56.536Z", "location_count": 8, "location_summary": "Detroit, Michigan • St Louis, Missouri • Charlotte, North Carolina + 5 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05856981" } ] }